Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2

BACKGROUND AND AIMS: Medical management of fistulising Crohn’s disease [CD] is constrained by the limited number of available therapies. We evaluated the efficacy of vedolizumab, a gut-selective α(4)β(7) integrin antagonist approved for treating moderately to severely active CD, in a subpopulation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Feagan, Brian G, Schwartz, David, Danese, Silvio, Rubin, David T, Lissoos, Trevor W, Xu, Jing, Lasch, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018899/
https://www.ncbi.nlm.nih.gov/pubmed/29471381
http://dx.doi.org/10.1093/ecco-jcc/jjy019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018899/
https://www.ncbi.nlm.nih.gov/pubmed/29471381
http://dx.doi.org/10.1093/ecco-jcc/jjy019

Ejemplares similares